A
Alain Fraisse
Researcher at National Institutes of Health
Publications - 216
Citations - 4883
Alain Fraisse is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Medicine & Pulmonary artery. The author has an hindex of 28, co-authored 197 publications receiving 3673 citations. Previous affiliations of Alain Fraisse include Aix-Marseille University & Paul Sabatier University.
Papers
More filters
Journal ArticleDOI
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.
Elizabeth Whittaker,Elizabeth Whittaker,Alasdair Bamford,Alasdair Bamford,Julia Kenny,Julia Kenny,Myrsini Kaforou,Christine E. Jones,Priyen Shah,Padmanabhan Ramnarayan,Padmanabhan Ramnarayan,Alain Fraisse,Owen G. Miller,Owen G. Miller,Patrick Davies,Filip Kucera,Joe Brierley,Marilyn McDougall,Marilyn McDougall,Michael J. Carter,Michael J. Carter,Adriana H. Tremoulet,Chisato Shimizu,Jethro Herberg,Jethro Herberg,Jane C. Burns,Hermione Lyall,Michael Levin +27 more
TL;DR: There was a wide spectrum of presenting signs and symptoms and disease severity, ranging from fever and inflammation to myocardial injury, shock, and development of coronary artery aneurysms, and comparison with the characteristics of other pediatric inflammatory disorders.
Journal ArticleDOI
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
Barbara Girerd,David Montani,Florence Coulet,Benjamin Sztrymf,Azzeddine Yaici,Xavier Jaïs,David-Alexandre Trégouët,Abílio Reis,Valérie Drouin-Garraud,Alain Fraisse,Olivier Sitbon,Dermot S. O'Callaghan,Gérald Simonneau,Florent Soubrier,Marc Humbert +14 more
TL;DR: ACVRL1 mutation carriers were characterized by a younger age at PAH diagnosis and had worse prognosis compared with other patients with PAH, suggesting more rapid disease progression.
Journal ArticleDOI
Outcome of acute fulminant myocarditis in children
TL;DR: Despite a severe presentation, the outcome of AFM is favourable and heart transplantation should be considered only when maximal supportive therapy does not lead to improvement.
Journal ArticleDOI
Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France
Alain Fraisse,Xavier Jaïs,Jean-Marc Schleich,Sylvie Di Filippo,Pascale Maragnès,Maurice Beghetti,Virginie Gressin,M. Voisin,Claire Dauphin,Pierre Clerson,François Godart,Damien Bonnet +11 more
TL;DR: In children, idiopathic/familial pulmonary arterial hypertension accounts for the majority of cases and a specific pulmonary arterials group in conjunction with congenital heart disease can be identified that resembles patients with idiopATHic pulmonary arterIAL hypertension.
Journal ArticleDOI
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study
Maurice Beghetti,Sheila G. Haworth,Damien Bonnet,Robyn J. Barst,Philippe Acar,Alain Fraisse,D. Dunbar Ivy,Xavier Jaïs,Ingram Schulze-Neick,Nazzareno Galiè,Adele Morganti,Jasper Dingemanse,Andjela Kusic-Pajic,Rudolphus Berger +13 more
TL;DR: Since FUTURE-1 and past studies suggest a favourable benefit–risk profile for bosentan at 2 mg kg−1 b.i.d., this dose is recommended for children with PAH and the new paediatric formulation was well tolerated.